#China #Shanghai #AP301 #Hyperphosphatemia #Alebund Pharmaceuticals

Alebund Pharmaceuticals Achieves Key Milestone with AP301

In a significant advancement within the biopharmaceutical industry, Alebund Pharmaceuticals (Jiangsu) Limited has announced that their New Drug Application (NDA) for AP301 capsules has received formal acceptance for review by China's National Medical Products Administration (NMPA). This groundbreaking medication is designed to tackle hyperphosphatemia in patients suffering from chronic kidney disease (CKD) who are undergoing maintenance dialysis.

AP301 is an innovative oral iron-based phosphate binder that distinguishes itself by its high phosphate-binding capability, ease of administration, and improved tolerability, thereby potentially enhancing adherence to treatment among patients. Not only does this formulation negate the need for chewing prior to swallowing, but its unique composition does not expand in volume upon contact with gastric fluid and is not absorbed into the bloodstream, significantly lowering the pill burden for patients.

The Pivotal RESPOND-1 Trial

The pivotal Phase III clinical trial, known as RESPOND-1, which was conducted across 50 sites in China and led by Professor Li Zuo of Peking University People's Hospital, consisted of 474 patients suffering from hyperphosphatemia due to maintenance dialysis. Participants were divided into two groups, one receiving AP301 and the other receiving sevelamer carbonate, with the treatments administered over a 52-week period. This study was designed to evaluate the long-term efficacy and safety of AP301.

The trial successfully met both its primary efficacy endpoints, showcasing significant superiority in serum phosphate reduction among patients prescribed AP301 compared to those receiving a lower dose of the comparator. Furthermore, the results demonstrated sustained phosphate reduction throughout the treatment duration, meeting the non-inferiority criteria set forth against sevelamer carbonate, validating the promising efficacy of the new medication.

Importance of Addressing Hyperphosphatemia

Hyperphosphatemia represents a prevalent complication in patients with end-stage renal disease undergoing dialysis, impacting around 95% of this patient cohort. Failure to manage elevated serum phosphate levels can lead to severe health issues such as vascular calcification, secondary hyperparathyroidism, renal osteodystrophy, and increased cardiovascular risks. Ongoing dietary restrictions and traditional phosphate binders have proven inadequate for many patients. Thus, the timely introduction of AP301 arrives as a hopeful solution, offering a better therapeutic alternative that aligns with the needs of this demographic.

Dr. Gavin Guoyao Xia, CEO and Co-founder of Alebund, acknowledged the significance of the NDA acceptance in furthering the company's ambition to innovate within the renal therapeutic space, emphasizing the commitment to facilitating long-term management strategies that prioritize both efficacy and tolerability. This innovation is poised to provide CKD patients a better quality of life and a more manageable treatment process.

Looking Ahead

As Alebund prepares for further regulatory scrutiny, they plan to expedite launch preparations, leveraging their robust manufacturing capabilities in Yangzhou. The company's ongoing dedication to advancing AP301 reveals a strong alignment with global demands for effective kidney disease management solutions.

In conclusion, the acceptance of the NDA for AP301 signals a transformational moment for patients battling hyperphosphatemia due to chronic kidney disease, underscoring the company's commitment to improving renal health outcomes worldwide. The landscape of renal pharmacotherapy may soon witness a substantial shift with the emergence of this innovative product.